Skip to content

US · TELA · MEDICAL - DEVICES

TELA Bio, Inc. (TELA) intrinsic value and stock valuation

$0.69as of 2026-11-21 · Mkt cap 40.94M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TELA Bio, Inc. DCF and intrinsic value

InvestorsCraft values TELA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TELA’s statements →

TELA Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Malvern, PA 19355 telabio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$80.3M+34.5% 5y CAGRd
20172025
Net income
-$-38.83M
20172025
Free cash flow
-$-28.67M
20172025
Total equity
$6.31M-33.6% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$80.3M$69.3M$58.5M$41.4M$29.5M
Operating income-$-33.76M-$-34.12M-$-44.08M-$-39.01M-$-29.45M
Net income-$-38.83M-$-37.84M-$-46.66M-$-44.3M-$-33.28M
EPSd-$-827.05K-$-1.33M-$-2.04M-$-2.72M-$-2.3M
Operating cash flow-$-28.22M-$-41.59M-$-40.86M-$-40.75M-$-30.43M
Capital expenditure-$-450K-$-990K-$-610K-$-1.87M-$-630K
Free cash flow-$-28.67M-$-42.58M-$-41.47M-$-42.62M-$-31.06M
Total assets$81.4M$87.3M$78.1M$67.9M$62.5M
Total debt$55.7M$43.1M$42.8M$41.5M$31.5M
Net debt$4.81M-$-9.61M-$-3.96M-$-560K-$-12.44M
Total equity$6.31M$28.5M$18.9M$14.3M$20.1M
Cash and short-term investments$50.8M$52.7M$46.7M$42M$43.9M
Income statement
20252024202320222021
Revenue$80.3M$69.3M$58.5M$41.4M$29.5M
Cost of revenue$25.9M$22.8M$18.3M$14.4M$10.7M
Gross profit$54.3M$46.5M$40.1M$27M$18.8M
Research and development expenses$9.22M$8.81M$9.62M$8.94M$6.74M
Selling, general and administrative expenses$78.9M$79.4M$74.6M$57.1M$41.5M
Other expenses$0.00-$-7.58M$0.00$0.00$0.00
Operating expenses$88.1M$80.6M$84.2M$66.1M$48.3M
Cost and expenses$114M$103.4M$102.5M$80.4M$58.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$5.25M$5.29M$5.22M$4.05M$3.6M
Depreciation and amortization$1.01M$1.01M$810K$1.19M$540K
Ebitda-$-32.35M-$-31.68M-$-40.63M-$-39.06M-$-29.14M
Operating income-$-33.76M-$-34.12M-$-44.08M-$-39.01M-$-29.45M
Total other income/expenses, net-$-4.85M-$-3.87M-$-2.59M-$-5.29M-$-3.83M
Income before tax-$-38.6M-$-37.98M-$-46.66M-$-44.3M-$-33.28M
Income tax expense$230K-$-140K$0.00$0.00$0.00
Net income-$-38.83M-$-37.84M-$-46.66M-$-44.3M-$-33.28M
Weighted average shares outstanding$47M$28.5M$22.9M$16.3M$14.5M
Weighted average diluted shares outstanding$47M$28.5M$22.9M$16.3M$14.5M
Balance sheet
20252024202320222021
Cash and short-term investments$50.8M$52.7M$46.7M$42M$43.9M
Net receivables$10.4M$10.1M$9.74M$6.62M$4.23M
Inventory$11M$12.8M$13.2M$11.8M$7.66M
Total current assets$75.6M$78.1M$71.7M$62.5M$59.1M
Property, plant and equipment, net$3.73M$4.08M$3.94M$2.91M$1.19M
Goodwill and intangible assets$1.36M$1.74M$2.12M$2.5M$2.3M
Long-term investments$250K$2.54M$270K$0.00$0.00
Total non-current assets$5.84M$9.25M$6.32M$5.41M$3.49M
Total assets$81.4M$87.3M$78.1M$67.9M$62.5M
Accounts payable$2.31M$2.15M$1.67M$1.53M$2.41M
Short-term debt$0.00$550K$560K$340K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18M$15.6M$17M$12.4M$10.6M
Long-term debt$55.7M$42.5M$42.2M$41.1M$31.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$57.1M$43.3M$42.2M$41.2M$31.9M
Capital lease obligations$0.00$1.39M$1.69M$1.2M$0.00
Total liabilities$75.1M$58.9M$59.2M$53.6M$42.5M
Common stock$40K$40K$20K$20K$10K
Retained earnings-$-397.56M-$-358.73M-$-320.89M-$-274.23M-$-229.93M
Accumulated other comprehensive income (loss)$90K$90K$90K$150K-$-50K
Total equity$6.31M$28.5M$18.9M$14.3M$20.1M
Total investments$250K$2.54M$270K$0.00$0.00
Total debt$55.7M$43.1M$42.8M$41.5M$31.5M
Net debt$4.81M-$-9.61M-$-3.96M-$-560K-$-12.44M
Cash flow statement
20252024202320222021
Net income-$-38.83M-$-37.84M-$-46.66M-$-44.3M-$-33.28M
Depreciation and amortization$1.01M$1.01M$810K$1.19M$540K
Stock-based compensation$3.8M$4.36M$5.03M$3.99M$3.66M
Change in working capital$1.5M-$-4.87M-$-1.67M-$-5.76M-$-3.47M
Accounts receivable-$-110K-$-760K-$-3.06M-$-2.42M-$-1.55M
Inventory-$-500K-$-2.97M-$-2.72M-$-6.07M-$-5.19M
Accounts payable$140K$480K$10K-$-880K$1.6M
Net cash provided by operating activities-$-28.22M-$-41.59M-$-40.86M-$-40.75M-$-30.43M
Investments in property, plant and equipment-$-450K-$-990K-$-610K-$-870K-$-630K
Acquisitions, net$1.29M$0.00$0.00$0.00$0.00
Net cash used for investing activities$850K$4.45M-$-600K-$-1.87M-$-630K
Common stock issued$11.8M$42.9M$46.3M$34.4M$580K
Common stock repurchased$100K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$25.8M$43.1M$46.3M$40.9M$580K
Net change in cash-$-1.84M$5.94M$4.97M-$-1.91M-$-30.46M
Cash at end of period$51.1M$52.9M$47M$42M$43.9M
Operating cash flow-$-28.22M-$-41.59M-$-40.86M-$-40.75M-$-30.43M
Capital expenditure-$-450K-$-990K-$-610K-$-1.87M-$-630K
Free cash flow-$-28.67M-$-42.58M-$-41.47M-$-42.62M-$-31.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TELA Bio, Inc.

        TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

        CEO
        Antony Koblish
        Employees
        218
        Beta
        1.34

        Explore

        Frequently asked questions

        What is the intrinsic value of TELA Bio, Inc. (TELA)?

        InvestorsCraft does not currently publish an intrinsic value for TELA. How the IC value is calculated.

        Is TELA undervalued?

        InvestorsCraft does not publish an undervaluation signal for TELA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.